HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

(2010) Charlotte Charpentier et al.   AIDS

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir

(2010) Vici Varghese et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Resistance to HIV-1 integrase inhibitors: A structural perspective

(2010) Jean-François Mouscadet et al.   DRUG RESISTANCE UPDATES

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

(2010) Eugenia Vispo et al.   HIV CLINICAL TRIALS

Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness

(2010) Zixin Hu et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

(2010) Jose M Gatell et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

(2010) D. da Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Retroviral intasome assembly and inhibition of DNA strand transfer

(2010) Stephen Hare et al.   NATURE

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

(2010) Olivia Goethals et al.   VIROLOGY

Resistance to Integrase Inhibitors

(2010) Mathieu Métifiot et al.   Viruses-Basel

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

(2009) Filippo Canducci et al.   AIDS

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

(2009) O. Delelis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure

(2009) S. Fransen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in a Novel Integrase-Deleted Cloning Vector

(2009) E. C. Reuman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

(2009) Damian J. McColl et al.   ANTIVIRAL RESEARCH

Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial

(2009) Nathalie De Castro et al.   CLINICAL INFECTIOUS DISEASES

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

(2009) Y. Yazdanpanah et al.   CLINICAL INFECTIOUS DISEASES

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

(2009) L. Wittkop et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

(2009) M. Wirden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evolution of raltegravir resistance during therapy

(2009) N. Sichtig et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens

(2009) Fausto Baldanti et al.   JOURNAL OF MEDICAL VIROLOGY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

(2009) O. Delelis et al.   NUCLEIC ACIDS RESEARCH

Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs

(2009) A. Alian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase

(2008) G. S. Jones et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

(2008) M KOBAYASHI et al.   ANTIVIRAL RESEARCH

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

(2008) Soo-Yon Rhee et al.   Retrovirology